ໜ້າທຳອິດDRREDDY • NSE
add
Dr Reddy's Laboratories Ltd
ປິດກ່ອນໜ້າ
₹1.195,35
ຂອບເຂດລາຄາໃນມື້
₹1.193,60 - ₹1.223,20
ຂອບເຂດລາຄາໃນປີ
₹1.074,00 - ₹1.421,49
ມູນຄ່າຮຸ້ນຕາມລາຄາຕະຫຼາດ
1,01 ລ້ານລ້ານ INR
ປະລິມານສະເລ່ຍ
1,48 ລ້ານ
ອັດຕາ P/E
18,96
ເງິນປັນຜົນ
0,66%
ຕະຫຼາດຂັ້ນຕົ້ນ
NSE
ໃນຂ່າວ
ການເງິນ
ໃບລາຍງານຜົນໄດ້ຮັບ
ລາຍໄດ້
ລາຍໄດ້ສຸດທິ
(INR) | ກ.ຍ. 2024info | ການປ່ຽນແປງ ປ/ປ |
---|---|---|
ລາຍໄດ້ | 80,16 ຕື້ | 16,51% |
ຄ່າໃຊ້ຈ່າຍການດຳເນີນການ | 29,72 ຕື້ | 24,54% |
ລາຍໄດ້ສຸດທິ | 12,55 ຕື້ | -15,18% |
ສ່ວນແບ່ງກຳໄລສຸດທິ | 15,66 | -27,20% |
ລາຍໄດ້ຕໍ່ຮຸ້ນ | 15,83 | -11,13% |
EBITDA | 22,02 ຕື້ | 8,53% |
ອັດຕາອາກອນທີ່ມີຜົນ | 30,01% | — |
ໃບດຸ່ນດ່ຽງ
ຊັບສິນທັງໝົດ
ໜີ້ສິນທັງໝົດ
(INR) | ກ.ຍ. 2024info | ການປ່ຽນແປງ ປ/ປ |
---|---|---|
ເງິນສົດ ແລະ ລົງທຶນໄລຍະສັ້ນ | 63,07 ຕື້ | -7,15% |
ຊັບສິນທັງໝົດ | 465,96 ຕື້ | 34,27% |
ໜີ້ສິນທັງໝົດ | 156,67 ຕື້ | 66,79% |
ຫຸ້ນທຶນທັງໝົດ | 309,28 ຕື້ | — |
ຮຸ້ນທີ່ຄ້າງຈ່າຍ | 833,05 ລ້ານ | — |
ລາຄາຕໍ່ມູນຄ່າທາງບັນຊີ | 3,26 | — |
ລາຍຮັບຈາກຊັບສິນ | 10,24% | — |
ລາຍຮັບຈາກທຶນ | 13,21% | — |
ກະແສເງິນສົດ
ການປ່ຽນແປງສຸດທິເປັນເງິນສົດ
(INR) | ກ.ຍ. 2024info | ການປ່ຽນແປງ ປ/ປ |
---|---|---|
ລາຍໄດ້ສຸດທິ | 12,55 ຕື້ | -15,18% |
ເງິນສົດຈາກການດໍາເນີນງານ | 9,32 ຕື້ | -48,03% |
ເງິນສົດຈາກການລົງທຶນ | -19,07 ຕື້ | -322,21% |
ເງິນສົດຈາກການເງິນ | 16,15 ຕື້ | 329,53% |
ການປ່ຽນແປງສຸດທິເປັນເງິນສົດ | 6,37 ຕື້ | 1,03% |
ການເງິນສະພາບຄ່ອງ | 3,92 ຕື້ | -72,47% |
ກ່ຽວກັບ
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
CEO
ສ້າງຕັ້ງ
1984
ສໍານັກງານໃຫຍ່
ເວັບໄຊ
ພະນັກງານ
27.048